Annamaria Ruzzo / Professoressa Associata

Ph.D. in Biochemical and Pharmacological methodologies.
As a researcher I was first trained in genetics and molecular biology of inherited diseases and then in molecular oncology and pharmacogenetics.
My research has been addressed mainly to the ?eld of translational studies in colorectal and gastric cancer.
orcid.org/0000-0003-2815-1890

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.

Loscocco F, Visani G, Ruzzo A, Bagaloni I, Fuligni F, Galimberti S, Di Paolo A, Stagno F, Pregno P, Annunziata M, Gozzini A, Barulli S, Gabucci E, Magnani M, Isidori A.Front Oncol. 2021 May 13;11:672287. doi: 10.3389/fonc.2021.672287. eCollection 2021.PMID: 34055641 Free PMC article.

MetaTropismDB: a database of organ-specific metastasis induced by human cancer cell lines in mouse models.

Giulietti M, Bastianoni M, Cecati M, Ruzzo A, Bracci M, Malavolta M, Piacenza F, Giacconi R, Piva F.Database (Oxford). 2020 Nov 25;2020:baaa100. doi: 10.1093/database/baaa100.PMID: 33238004 Free PMC article.

TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy.

Graziano F, Fischer NW, Bagaloni I, Di Bartolomeo M, Lonardi S, Vincenzi B, Perrone G, Fornaro L, Ongaro E, Aprile G, Bisonni R, Prisciandaro M, Malkin D, Gariépy J, Fassan M, Loupakis F, Sarti D, Del Prete M, Catalano V, Alessandroni P, Magnani M, Ruzzo A.Cancers (Basel). 2020 Jul 24;12(8):2049. doi: 10.3390/cancers12082049.PMID: 32722340 Free PMC article.

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab.

Ruzzo A, Graziano F, Bagaloni I, Di Bartolomeo M, Prisciandaro M, Aprile G, Ongaro E, Vincenzi B, Perrone G, Santini D, Fornaro L, Vivaldi C, Tomasello G, Loupakis F, Lonardi S, Fassan M, Valmasoni M, Sarti D, Lorenzini P, Catalano V, Bisonni R, Del Prete M, Collina G, Magnani M.Gastric Cancer. 2020 Nov;23(6):1064-1074. doi: 10.1007/s10120-020-01078-0. Epub 2020 May 5.PMID: 32372141 Free PMC article.

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M.Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.PMID: 32005869 Free PMC article.

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M.Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.PMID: 31395900 Free PMC article. Clinical Trial.

XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT.

Visani G, Loscocco F, Bagaloni I, Ruzzo A, Fuligni F, Graziano F, Magnani M, Isidori A.Bone Marrow Transplant. 2020 Apr;55(4):818-820. doi: 10.1038/s41409-019-0572-7. Epub 2019 Jun 23.PMID: 31231123 No abstract available.

A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4.

Campopiano R, Ferese R, Buttari F, Femiano C, Centonze D, Fornai F, Biagioni F, Chiaravalloti MA, Magnani M, Giardina E, Ruzzo A, Gambardella S.Front Neurol. 2020 Jan 15;10:1331. doi: 10.3389/fneur.2019.01331. eCollection 2019.PMID: 32010037 Free PMC article.

Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.

Wong GS, Zhou J, Bin Liu J, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ.Nat Med. 2018 Oct;24(10):1627. doi: 10.1038/s41591-018-0168-6.PMID: 30093730

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.

Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ.Nat Med. 2018 Jul;24(7):968-977. doi: 10.1038/s41591-018-0022-x. Epub 2018 May 28.PMID: 29808010 Free PMC article.